Ionis Pharmaceuticals

#Neurology #Cardiometabolic #Renal #Rare Disease #Antisense Oligonucleotide Therapeutics

Ionis Pharmaceuticals (NASDAQ: IONS) is a Carlsbad, California-based antisense oligonucleotide (ASO) drug discovery and development company with a deep pipeline spanning neurology, cardiometabolic disease, renal disease, and rare disorders.

Company Info

Sector:Antisense RNA Therapeutics

Headquarters:Carlsbad, California, USA

Founded:1989

Website:ionis.com/

Upcoming Milestones & Key Dates

2026-08-05

Earnings

Q2 2026 earnings

2026-10-15

Conference

EHA / ASH presentations

Clinical Development Pipeline

Tryngolza (olezarsen)

Target: APOC3 mRNA

Familial chylomicronemia syndrome (FCS); severe hypertriglyceridemia (sHTG)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Wainua (eplontersen)

Target: TTR mRNA

Heredit transthyretin-mediated amyloid polyneuropathy (ATTRv-PN); ATTR-CM

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Sapablursen

Target: TMPRSS6 mRNA

Polycythemia vera

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use ↗

Ionis Pharmaceuticals secured an additional FDA approval for Tryngolza (olezarsen), expanding its market to include severe hypertriglyceridemia beyond the original familial chylomicronemia syndrome (FCS) indication.

Leadership Team

Brett P. Monia

Chief Executive Officer

Elizabeth L. Hougen

Chief Financial Officer

C. Frank Bennett

Chief Scientific Officer

Careers & Job Openings

See all open roles

Various

Apply Now →